Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2022
December 2022, Vol 12, No 12
December 2022, Vol 12, No 12
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
Self-insured employers, perhaps even yours, are being presented with programs called “specialty carve-outs” as an opportunity for saving significant money on the drug portion of their employee benefits.
Read More ›
Understanding the Evolving Landscape for the Diagnosis and Treatment of AML
By
Patricia Stewart
NCCN 2022 Hematologic Malignancies
,
Leukemia
The treatment of acute myeloid leukemia (AML) has entered a new era, with the use of more potent therapies, such as targeted agents and venetoclax (Venclexta).
Read More ›
Female Patients Undergoing Cancer Treatment Rarely Asked About Sexual Health
By
Patricia Stewart
ASTRO 2022 Highlights
Results from a new study revealed that radiation oncologists tend to discuss sexual side effects in women undergoing treatment for cervical cancer far less frequently than they discuss sexual side effects in men undergoing treatment for prostate cancer.
Read More ›
Shortened Radiation Schedule Safe and Effective in High-Risk Prostate Cancer
By
Patricia Stewart
ASTRO 2022 Highlights
A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial.
Read More ›
Adding Radiation to Systemic Therapy Improves Survival in Patients with Advanced Hepatocellular Cancer
By
Patricia Stewart
ASTRO 2022 Highlights
According to findings from a phase 3 trial presented at ASTRO 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life.
Read More ›
Improved Overall Survival with First-Line Brentuximab Vedotin plus AVD in Patients with Advanced Hodgkin Lymphoma: Results from the ECHELON-1 Trial
By
Patricia Stewart
NCCN 2022 Hematologic Malignancies
Updated results from the ECHELON-1 clinical trial showed that the combination of brentuximab vedotin (Adcetris; BV) plus doxorubicin, vinblastine, and dacarbazine (AVD) as first-line therapy improves overall survival (OS) in patients with stage III-IV classical Hodgkin lymphoma compared with standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
Read More ›
AVBCC Panel Discusses the Current and Future State of Value-Based Agreements
By
William King
AVBCC Summit Highlights
,
Value-Based Care
At the AVBCC 12th Annual Summit in 2022, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead.
Read More ›
Targeted Therapy with Brentuximab Vedotin Significantly Lowers Relapse Risk in Pediatric Patients with High-Risk Hodgkin Lymphoma
In the Literature
According to published results from a phase 3, prospective, multicenter, randomized clinical trial, the addition of the CD-30–targeted antibody–drug conjugate brentuximab vedotin (Adcetris) to standard chemotherapy can reduce the risk for relapse in this population of patients while providing a better tolerability profile.
Read More ›
Standardized Biosimilar Protocol Leads to Higher Conversion Rates and Lower Costs
By
William King
Biosimilars
Standardizing biosimilar adoption in oncology through the electronic health record can improve biosimilar utilization and reduce health system costs.
Read More ›
Engaging Patients Through Care Management Services
By
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM
Practice Management
Care management services are designed to engage patients as active partners in their healthcare so they can effectively manage their complex medical conditions.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes